BACKGROUND: Aim of this study was to describe longitudinal assessments of handgrip strength, strength of thigh muscles, and self-reported physical performance in patients with glioblastoma after neurosurgical intervention undergoing chemoradiation. METHODS: Strength testing was performed in 24 Austrian glioblastoma patients (m:f = 19:5, 52 ± 14a, BMI = 26 ± 3 kg/m²) at baseline and follow up after chemoradiation (interval between baseline and follow up = 14 ± 9 weeks). Isokinetic testing of knee extension/flexion was performed by using a Biodex 3 dynamometer. Handgrip strength was measured by using a Jamar hand-dynamometer. Physical performance was assessed by using the subscales "physical functioning" and "role physical" of the SF-36 Health Survey. RESULTS:Peak torque of knee extensors (peak torque) were clearly lower than expected for age- and sex-related values (p < 0.0001). In comparison with age- and sex-related reference values, deficits of "role physical" (p < 0.0001) and "physical functioning" (p = 0.010) were found. Effects of measurements of muscle strength on "physical functioning" were significant (peak torque:p < 0.001; handgrip strength:p < 0.001). No significant change could be detected after follow up for peak torque (p = 0.337), handgrip strength (p = 0.995), "physical functioning" (p = 0.824), and "role physical" (0.594). CONCLUSIONS: In this study, notable deficits especially in muscular strength of thigh muscles and general physical performance of patients with glioblastoma have been found before and after chemoradiation. Reduced muscle strength and impaired self-reported physical performance seem to be clinically relevant functional deficits in (Austrian) glioblastoma patients. Therefore, rehabilitation and supportive care should also include options to increase muscle strength.
RCT Entities:
BACKGROUND: Aim of this study was to describe longitudinal assessments of handgrip strength, strength of thigh muscles, and self-reported physical performance in patients with glioblastoma after neurosurgical intervention undergoing chemoradiation. METHODS: Strength testing was performed in 24 Austrian glioblastomapatients (m:f = 19:5, 52 ± 14a, BMI = 26 ± 3 kg/m²) at baseline and follow up after chemoradiation (interval between baseline and follow up = 14 ± 9 weeks). Isokinetic testing of knee extension/flexion was performed by using a Biodex 3 dynamometer. Handgrip strength was measured by using a Jamar hand-dynamometer. Physical performance was assessed by using the subscales "physical functioning" and "role physical" of the SF-36 Health Survey. RESULTS: Peak torque of knee extensors (peak torque) were clearly lower than expected for age- and sex-related values (p < 0.0001). In comparison with age- and sex-related reference values, deficits of "role physical" (p < 0.0001) and "physical functioning" (p = 0.010) were found. Effects of measurements of muscle strength on "physical functioning" were significant (peak torque:p < 0.001; handgrip strength:p < 0.001). No significant change could be detected after follow up for peak torque (p = 0.337), handgrip strength (p = 0.995), "physical functioning" (p = 0.824), and "role physical" (0.594). CONCLUSIONS: In this study, notable deficits especially in muscular strength of thigh muscles and general physical performance of patients with glioblastoma have been found before and after chemoradiation. Reduced muscle strength and impaired self-reported physical performance seem to be clinically relevant functional deficits in (Austrian) glioblastomapatients. Therefore, rehabilitation and supportive care should also include options to increase muscle strength.
Authors: Joshua M Drouin; Tamara C Valovich-mcLeod; Sandra J Shultz; Bruce M Gansneder; David H Perrin Journal: Eur J Appl Physiol Date: 2003-09-24 Impact factor: 3.078
Authors: S D Anker; P Ponikowski; S Varney; T P Chua; A L Clark; K M Webb-Peploe; D Harrington; W J Kox; P A Poole-Wilson; A J Coats Journal: Lancet Date: 1997-04-12 Impact factor: 79.321
Authors: Markus Weiler; Christian Hartmann; Dorothee Wiewrodt; Ulrich Herrlinger; Thierry Gorlia; Oliver Bähr; Richard Meyermann; Michael Bamberg; Marcos Tatagiba; Andreas von Deimling; Michael Weller; Wolfgang Wick Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-14 Impact factor: 7.038
Authors: Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman Journal: J Neurooncol Date: 2009-02-11 Impact factor: 4.130
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Martin Hülsmann; Michael Quittan; Rudolf Berger; Richard Crevenna; Christoph Springer; Martin Nuhr; Deddo Mörtl; Petra Moser; Richard Pacher Journal: Eur J Heart Fail Date: 2004-01 Impact factor: 15.534
Authors: Kimberly E Alexander; Bruce A Cooper; Steven M Paul; Patsy Yates; Bradley E Aouizerat; Christine Miaskowski Journal: Qual Life Res Date: 2016-05-09 Impact factor: 4.147
Authors: Bruno Maehr; Mohammad Keilani; Christoph Wiltschke; Marco Hassler; Thomas Licht; Christine Marosi; Elisabeth Huetterer; Fadime Cenik; Richard Crevenna Journal: Wien Med Wochenschr Date: 2016-01-12